Strategic Acquisition Opportunity arises from Healthome's acquisition of Kailos Genetics in May 2023, indicating potential for integrated genomics services, expanded distribution, and combined client networks. Sales outreach can target Healthome’s portfolio to explore joint offerings or cross-sell Kailos’ genetic testing capabilities to their customers.

Clinical Expansion Kailos operates as a CLIA-certified and CAP-accredited lab with physician-ordered tests, presenting a strong value proposition for healthcare systems and clinics seeking reliable, compliant genetic testing. Target hospital networks, specialty clinics, and telemedicine platforms seeking integrated genetic testing workflows.

Eye Health Focus Active collaboration with Advancing Sight Network and development of the OcularGeneScreen panel signals opportunities in ophthalmology and vision research. Propose partnerships with eye care providers, research institutions, and post-mortem tissue programs to scale ocular genetics testing.

Workplace Health Programs Past launches of Assure Sentinel and workplace COVID-19 testing indicate capability in large-scale, ongoing health programs. Markets include corporate employers, education systems, and public sector clients seeking ongoing biosurveillance or pharmacogenetic routing in employee health initiatives.

Pharmacogenetics Potential Partnerships like Intermountain Health for pharmacogenetic testing demonstrate demand for pharmacogenomics within healthcare networks. Sales focus on integrated pharmacogenetic services for medication tailoring, expanding to managed care organizations, integrated delivery networks, and health systems investing in personalized medicine.